uploads/2018/11/GILD3.png

What Does Gilead Sciences’ Bottom-Line Trend Indicate?

By

Updated

Bottom line

Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter. The company’s income tax provision also decreased from $959.0 million in the third quarter of 2017 to $565.0 million in the third quarter.

The continued decrease in the top line and higher operating expenses caused Gilead Sciences’ net income to fall from $2.72 billion in the third quarter of 2017 to $2.1 billion in the third quarter, which translated into a net EPS of $1.60 in the third quarter. Gilead Sciences’ net EPS was $2.06 in the third quarter of 2017.

Article continues below advertisement

Geographic performance

Gilead Sciences geographic performance includes the US, Europe, and Other International segments. The company’s US revenues decreased from $4.54 billion in the third quarter of 2017 to $4.13 billion in the third quarter.

The company’s revenues from Europe decreased from $1.2 billion in the third quarter of 2017 to $873.0 million in the third quarter. Gilead Sciences’ revenues from the Other International segment decreased from $663.0 million in the third quarter of 2017 to $451.0 million in the third quarter.

Gilead Sciences’ cash per share stands at $19.97. In comparison, Bristol-Myers Squibb (BMY), Merck (MRK), and Pfizer’s (PFE) cash per share stand at $4.19, $2.83, and $2.25, respectively.

Next, we’ll discuss Gilead Sciences’ HIV sales trend.

Advertisement

More From Market Realist